NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

描述(由申请者提供)：本申请的总体目标是让Farber/Partners癌症护理(DF/PCC)成为NCTN的主要学术参与网站，并成为NCTN活动的主要贡献者。DF/PCC是一家合资企业，专注于由三个哈佛附属机构进行临床试验和临床研究人员培训：达纳-法伯癌症研究所、布里格姆妇女医院和马萨诸塞州综合医院。所有这些公司都是癌症临床研究的国家领导者，并通过完善的统一临床试验计划团结一致地工作。具体目标是：提供领导者来开发和进行临床试验，并通过大量、稳健的应计项目支持NCTN。虽然DF/PCC将把联盟网络集团作为其主要附属机构，但学院将继续与各种网络集团保持密切的历史关系。通过多个PD/PI模式、一支积极参与的跨学科教师队伍和强大的业务基础设施，DF/PCC将为试验开发试验提供高级科学投入；确定将提交给 NCTN；在我们的临床试验组合中确定NCTN试验的优先顺序；确保及时激活；提供培训和指导；公平分配资金；并确保参与地点的遵守。DF/PCC将影响NCTN，它将通过1)指导委员会的科学领导；2)参与CIRB；3)执行和委员会的领导和成员；4)执行和委员会的领导以及委员会的成员；5)作为附属的私人投资机构；6)应计方面的领导；以及7)培训新一代参与国家临床试验网络企业，从而确定新的治疗癌症患者的标准。

DESCRIPTION (provided by applicant): The overall goal of this application is for Farber/Partners Cancer Care (DF/PCC) to serve as a Lead Academic Participating Site in NCTN and become a leading contributor to NCTN activities. DF/PCC is a joint venture focused on conducting clinical trials and clinical investigator training by across three Harvard- affiliate institutions: Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital. All are national leaders in cancer clinical research and work cohesively through a well- established unified clinical trials program. Specific aims are: provide leaders to develop and conduct clinical trials, and support NCTN through substantial, robust accrual. While DF/PCC will have as its primary affiliation the Alliance Network Group, faculties will continue their strong historical relationships with a variety of Network Groups. Through a multiple PD/PI model, an engaged interdisciplinary faculty, and a strong operational infrastructure, DF/PCC will provide senior scientific input to trial development trials; identify novel trials to be brought to NCTN; prioritize NCTN trials within our clinical trials portfolio; assure timely activation; provid training and mentoring; distribute funding fairly; and ensure adherence at participating sites. DF/PCC will impact NCTN, which will define new standards of care for adult patients with cancer through 1) scientific leadership in the Steering Committees; 2) participation in CIRB; 3) executive and committee leadership and membership; 4) executive and committee leadership, as well as committee membership; 5) serving as affiliated PIs; 6) leadership in accrual; and 7) training a new generation to participate in the national clinical trials network enterprise.